IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced fourth-quarter 2009 revenue of $599.2 million, up 3
percent year over year and down 3 percent constant dollar, compared
with $580.9 million in the 2008 fourth quarter. Net income for the
2009 fourth quarter was $71.5 million and diluted earnings per
share was $0.39 compared with net income of $98.5 million and EPS
of $0.54 in the year-earlier period. After adjusting for $27.7
million of charges in the quarter related to the previously
announced restructuring, certain asset impairments, merger costs
and certain other items, net income on a non-GAAP basis for the
fourth quarter of 2009 was $95.1 million compared with $90.6
million in the year-earlier period, and non-GAAP EPS was $0.52
compared with $0.50 in the 2008 fourth quarter (See Note c to the
financial tables).
“IMS finished the year with an improved fourth-quarter
performance, reflecting solid sequential revenue growth and better
demand in the second half of the year,” said David R. Carlucci, IMS
chairman and CEO. “Our cost reduction plans remain on track, and we
achieved exceptional cash flow results throughout the year. We
continue to benefit from our industry-leading role, and are
strategically positioned to help clients transform their
businesses.”
Operating income in the fourth quarter of 2009 was $106.3
million compared with $126.6 million in operating income in the
year-earlier period. When adjusted for the restructuring charge,
merger costs and certain other items, operating income on a
non-GAAP basis for this year’s fourth quarter would have been
$134.0 million, compared with $136.0 million in the 2008 fourth
quarter (See Note c to the financial tables).
Preliminary net cash provided by operating activities on a GAAP
basis for the fourth quarter of 2009 was $195.1 million, and $542.6
million in the 2009 full year. Fourth-quarter 2009 preliminary free
cash flow on a non-GAAP basis was $138.0 million, bringing the
total for full-year 2009 to $543.1 million (See Note d to the
financial tables).
Full-Year Results
For the 2009 full year, revenues were $2,189.7 million, down 6
percent or 4 percent constant dollar, compared with revenues of
$2,329.5 million in 2008. Net income for 2009 was $258.5 million
and diluted earnings per share was $1.42 compared with net income
of $311.3 million and EPS of $1.70 the year earlier. After
adjusting for $159.5 million of charges in 2009 related to the
previously announced restructuring, certain asset impairments,
merger costs and certain other items, net income on a non-GAAP
basis for the 2009 full year was $315.6 million compared with
$311.7 million in 2008, and non-GAAP EPS was $1.73 compared with
$1.70 a year earlier (See Note c to the financial tables).
Including the restructuring charge, certain asset impairments,
merger costs and certain other items, operating income for
full-year 2009 was $270.9 million, compared with $498.3 million in
2008. When adjusted for these items, operating income on a non-GAAP
basis for 2009 would have been $430.4 million, compared with $511.5
million in 2008 (See Note c to the financial tables).
Balance Sheet Highlights
IMS’s cash and cash equivalents as of December 31, 2009 totaled
$380.3 million, compared with $215.7 million on December 31, 2008.
Total debt as of December 31, 2009 was $1,244.7 million, down from
$1,404.2 million at year-end 2008.
Share Repurchase Program, Shares Outstanding
No IMS shares were repurchased during the fourth quarter of
2009. A total of 9.5 million shares remain authorized and available
to repurchase under the current Board of Directors’
authorization.
The number of shares outstanding as of December 31, 2009 was
approximately 182.7 million, compared to 182.4 million as of
September 30, 2009.
About IMS
Operating in more than 100 countries, IMS Health is the world’s
leading provider of market intelligence to the pharmaceutical and
healthcare industries. With $2.2 billion in 2009 revenue and more
than 50 years of industry experience, IMS offers leading-edge
market intelligence products and services that are integral to
clients’ day-to-day operations, including product and
portfolio management capabilities; commercial
effectiveness innovations; managed care and consumer health
offerings; and consulting and services solutions that improve
productivity and the delivery of quality healthcare worldwide.
Additional information is available at
http://www.imshealth.com.
Forward-Looking Statements
This filing contains statements that may constitute
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Although the Company believes the expectations contained in its
forward-looking statements are reasonable, it can give no assurance
that such expectations will prove correct. This information may
involve risks and uncertainties that could cause actual results of
the Company to differ materially from the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to (i) uncertainties
associated with the proposed sale of the Company to an entity
created by certain affiliates of TPG Capital, L.P. and the Canada
Pension Plan Investment Board, including uncertainties relating to
the expected timing of the completion of the transaction and the
ability to complete the transaction, (ii) regulatory, legislative
and enforcement initiatives, particularly in the areas of data
access and utilization and tax, (iii) the risks associated with
operating on a global basis, including fluctuations in the value of
foreign currencies relative to the U.S. dollar, and the ability to
successfully hedge such risks, (iv) to the extent unforeseen cash
needs arise, the ability to obtain financing on favorable terms,
(v) to the extent the Company seeks growth through acquisitions and
joint ventures, the ability to identify, consummate and integrate
acquisitions and joint ventures on satisfactory terms, (vi) the
ability to develop new or advanced technologies and systems for its
businesses on time and on a cost effective basis, (vii)
deterioration in economic conditions, particularly in the
pharmaceutical, healthcare or other industries in which the
Company’s customers operate, and (viii) uncertainties associated
with completion of the Company’s restructuring plans and the impact
of the restructuring activities on the Company’s business and
financial results, including the timing of the activities and the
associated costs and the ability to achieve projected cost savings.
Additional information on factors that may affect the business and
financial results of the Company can be found in the filings of the
Company made from time to time with the Securities and Exchange
Commission. The Company undertakes no obligation to correct or
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Table 1
IMS Health
GAAP Income Statement
Three Months Ended December
31
(unaudited, in millions except
per share)
2009GAAP
2008
GAAP
% Fav
(Unfav)
Non-GAAP
Constant $
Growth %
Revenue (a) (b) Commercial Effectiveness $
310.9 $ 286.9 8 % 2
Product and Portfolio Management 181.0 176.5
3 (3 ) New Business Areas
107.3 117.5
(9 ) (12 ) Total 599.2
580.9 3 (3 )
Revenue Detail:
Information & Analytics (“I&A”) Revenue
452.9
432.2 5 (1 ) Consulting & Services (“C&S”) Revenue
146.3 148.7 (2 ) (6 ) Total
Revenue 599.2 580.9 3 (3 )
Operating Expenses (b)
Operating Costs of I&A (187.6 )
(180.5 ) (4 ) Direct and Incremental
Costs of C&S (73.5 ) (72.6 )
(1 ) External-use Software Amortization
(9.9 ) (11.7 ) 15 Selling and
Administrative (171.3 ) (157.2 )
(9 ) Depreciation and Other Amortization
(22.9 ) (23.0 ) 0 Accelerated
Depreciation and Amortization (2.2 ) 0.0
NM Severance, impairment and other charges
(14.6 ) (9.4 ) (55 )
Merger costs (11.0
) 0.0 NM
Total (492.9 ) (454.4 )
(8 ) Operating Income (a) 106.3
126.6 (16 ) % (27 )
Interest expense, net (7.2 )
(7.8 ) 8 Gains from investments, net
0.6 0.0 NM Other Expense, net
(2.9 )
(13.7 ) 79 Pretax
Income 96.8 105.1 (8 )
Provision for Income Taxes (25.1
) (5.4
) NM Net Income (c) 71.7
99.7 (28 ) Less: Net Income
Attributable to Non-Controlling Interests
0.2 1.3
87 Net Income Attributable to IMS Health, Inc.
71.5 98.5 (27 ) Diluted
EPS: Total Diluted EPS $ 0.39 $
0.54 (28 ) Shares Outstanding:
Weighted Average Diluted 183.6 182.2
End-of-Period Actual 182.7 181.5 Weighted
Average Basic 182.7 181.7
The accompanying notes are an
integral part of these financial tables.
Table 2
IMS Health
GAAP Income Statement
Twelve Months Ended December
31
(unaudited, in millions except
per share)
2009GAAP
2008GAAP
% Fav
(Unfav)
Non-GAAP
Constant $
Growth %
Revenue (a) (b) Commercial Effectiveness $
1,103.9 $ 1,153.5 (4 ) %
(3 ) Product and Portfolio Management
683.9 721.4 (5 ) (3 )
New Business Areas 402.0
454.7 (12 ) (8
) Total 2,189.7 2,329.5 (6
) (4 )
Revenue Detail:
Information & Analytics (“I&A”) Revenue
1,706.7
1,787.5 (5 ) (3 ) Consulting & Services (“C&S”) Revenue
483.0 542.0
(11
)
(9 ) Total Revenue 2,189.7 2,329.5 (6 ) (4 )
Operating
Expenses (b) Operating Costs of I&A (715.8
) (757.0 ) 5 Direct and Incremental
Costs of C&S (250.4 ) (275.2 )
9 External-use Software Amortization (40.4
) (49.7 ) 19 Selling and
Administrative (661.5 ) (650.2 )
(2 ) Depreciation and Other Amortization
(91.3 ) (89.6 ) (2 )
Accelerated Depreciation and Amortization (4.2
) 0.0 NM Severance, impairment and other
charges (144.3 ) (9.4 ) NM
Merger costs (11.0
) 0.0 NM
Total (1,918.9 ) (1,831.2 )
(5 ) Operating Income (a) 270.9
498.3 (46 ) % (54 )
Interest expense, net (33.0 )
(34.5 ) 4 Gains from investments, net
0.0 0.4 NM Other Expense, net
(1.3 )
(41.4 ) NM Pretax
Income 236.6 422.8 (44 )
Provision for Income Taxes 24.0
(106.2 ) NM
Net Income (c) 260.6 316.6 (18 )
Less: Net Income Attributable to Non-Controlling
Interests 2.2
5.3 59 Net Income
Attributable to IMS Health, Inc. 258.5 311.3
(17 ) Diluted EPS: Total Diluted
EPS $ 1.42 $ 1.70 (16
) Shares Outstanding: Weighted Average
Diluted 182.6 183.6 End-of-Period Actual
182.7 181.5 Weighted Average Basic
182.4 182.8
The accompanying notes are an
integral part of these financial tables.
Table 3
IMS Health
Selected Consolidated Balance
Sheet Items
(unaudited, in
millions)
Dec. 31, 2009
Dec. 31, 2008
Cash and cash equivalents $ 380.3
$ 215.7 Accounts receivable, net
322.6 382.8
Long-term debt 1,244.7 1,404.2
The accompanying notes are an
integral part of these financial tables.
Table 4
IMS Health
Preliminary GAAP Cash Flows
from Operating Activities
Year Ended December 31
(unaudited, in
millions)
2009
GAAP
Net Income $ 260.6 Adjustments to
Reconcile Net Income to Net Cash Provided by Operating
Activities: Depreciation and Amortization 135.9
Bad Debt Expense 2.9 Deferred Income Taxes
(44.9 ) Gain on Sale of Assets, net
(2.3 ) Non-Cash Stock-Based Compensation
Charges 32.5 Non-Cash Severance, Impairment and
Other 32.4 Net Tax Benefit on Stock-Based
Compensation (4.6 ) Excess Tax Benefits from
Stock-Based Compensation (0.1 ) Change in
Assets and Liabilities, Excluding Effects from Acquisitions and
Dispositions: Net Decrease in Accounts Receivable
52.3 Net Decrease in Work-In-Process Inventory
1.9 Net Decrease in Prepaid Expenses and Other Current
Assets 8.8 Net Decrease in Accounts Payable
(15.6 ) Net Increase in Accrued and Other Current
Liabilities 30.1 Net Increase in Accrued Severance,
Impairment and Other 83.7 Net Increase in Deferred
Revenues 31.9 Net Decrease in Accrued Income
Taxes (76.9 ) Net Decrease in Pension Assets,
net of Liabilities 10.0 Net Decrease in Other
Long-Term Assets, net of Other Long-Term Liabilities
4.0 Net Cash Provided by Operating
Activities (d) $ 542.6
The accompanying notes are an
integral part of these financial tables.
IMS Health
NOTES TO FINANCIAL TABLES
a) Reference to Non-GAAP Constant-Dollar Growth. “Non-GAAP
Constant-dollar growth” rates eliminate the impact of
year-over-year foreign currency fluctuations (Tables 1 and 2). IMS
reports results in U.S. dollars but does business on a global
basis. Exchange rate fluctuations affect the rates at which IMS
translates foreign revenues and expenses into U.S. dollars and have
important effects on results. In order to illustrate these effects,
IMS provides the magnitude of changes in revenues and operating
income in constant-dollar terms. IMS uses results at
constant-dollar rates for purposes of global business
decision-making, including developing budgets and managing
expenditures. IMS management believes this information, when read
together with U.S. GAAP results, facilitates a comparative view of
business growth. Constant-dollar rates are not prepared under U.S.
GAAP and are not a replacement for the more comprehensive
information for investors included in IMS’s U.S. GAAP results. The
method IMS uses to prepare constant-dollar rates differs in
significant respects from U.S. GAAP and is likely to differ from
the methods used by other companies.
b) Revenue and operating expenses in 2008 reflect
reclassifications to make them comparable with the 2009
presentation.
c) Net income attributable to IMS Health, fully diluted EPS and,
where applicable, operating income for the three and twelve months
ended December 31, 2009 included the following notable items:
- In Merger costs, $11.0 million
of expense ($0.06 EPS impact for the three and twelve months ended
December 31, 2009) recorded in the three months ended December 31,
2009 related to the proposed acquisition of the Company by
Healthcare Technology Holdings, Inc., an entity created by certain
affiliates of TPG Capital, L.P. and the Canada Pension Plan
Investment Board.
- In Severance, impairment and
other charges, $1.3 million and $105.6 million of restructuring
charges ($0.9 million and $76.9 million net of taxes, or $0.01 and
$0.42 EPS impact) for the three and twelve months ended December
31, 2009, respectively, recorded during the six months ended
December 31, 2009 as a result of the streamlining program announced
by the Company in July 2009 in response to accelerating healthcare
marketplace dynamics compounded by a sustained economic
downturn.
- In Accelerated depreciation and
amortization, $2.2 million and $4.2 million ($1.6 million and $3.1
million net of taxes, or $0.01 and $0.02 EPS impact) for the three
and twelve months ended December 31, 2009, respectively, of
accelerated depreciation and amortization recorded during the six
months ended December 31, 2009 related to office lease and
intangible impairments as part of the streamlining program noted
above.
- In Severance, impairment and
other charges, $13.3 million and $38.7 million of charges ($11.2
million and $29.3 million net of taxes, or $0.06 and $0.16 EPS
impact) for the three and twelve months ended December 31, 2009,
respectively, recorded in the three months ended June 30, 2009 and
the three months ended December 31, 2009 for supplier
contract-related charges to be incurred with no future economic
benefit, the write-down of certain capitalized software and other
assets to their net realizable values and other items.
- In Provision for income taxes, a
$63.2 million net tax benefit ($0.35 EPS benefit) for the twelve
months ended December 31, 2009 due to the reorganization of certain
subsidiaries completed during the three months ended March 31,
2009, which resulted in a foreign exchange loss recognized for tax
purposes.
- After adjusting for these items
and the phasing of foreign exchange gains ($1.1 million net of
taxes, or $0.01 EPS impact for the three months ended December 31,
2009), operating income, net income attributable to IMS Health and
diluted EPS on a non-GAAP basis would have been $134.0 million and
$430.4 million, $95.1 million and $315.6 million and $0.52 and
$1.73 for the three and twelve months ended December 31, 2009,
respectively.
Net income attributable to IMS Health, fully diluted EPS and,
where applicable, operating income for the three and twelve months
ended December 31, 2008 included the following notable items:
- In Selling and administrative
expenses, $3.7 million of expense ($2.4 million net of taxes, or
$0.01 EPS impact for the twelve months ended December 31, 2008)
recorded in the three months ended September 30, 2008 related to
the Voluntary Disclosure Program at the Company’s Government
Solutions subsidiary.
- In Severance, impairment and
other charges, a $9.4 million charge ($6.9 million net of taxes, or
$0.04 EPS impact for the three and twelve months ended December 31,
2008) recorded in the three months ended December 31, 2008 for the
write-off of certain capitalized software assets resulting from the
discontinuation of certain IMS products at the end of 2008.
- In Other expense, net, a $16.1
million foreign exchange loss ($14.5 million net of taxes, or $0.08
EPS impact for the three and twelve months ended December 31, 2008)
related to the liquidation of non-functional currency Venezuelan
Bolívars held at the Company’s Swiss operating subsidiary and a
$4.0 million gain ($2.6 million net of taxes, or $0.01 EPS benefit
for the three and twelve months ended December 31, 2008) related to
the sale of certain assets in the Company’s Latin America region,
both recorded in the three months ended December 31, 2008.
- In Provision for income taxes, a
$20.7 million net tax benefit ($0.11 EPS benefit for the three and
twelve months ended December 31, 2008) as a result of a non-U.S.
reorganization involving several IMS subsidiaries recorded in the
three months ended December 31, 2008. Additionally, in Provision
for income taxes, a $3.9 million tax phasing adjustment ($0.02 EPS
impact) was reflected in the non-GAAP measures for the three months
ended December 31, 2008 arising from the expiration of both a
non-U.S. agreement and certain non-U.S. statutes of
limitations.
- After adjusting for these items
and the phasing of foreign exchange losses ($1.9 million net of
taxes, or $0.01 EPS benefit for the three months ended December 31,
2008), operating income, net income attributable to IMS Health and
diluted EPS on a non-GAAP basis would have been $136.0 million and
$511.5 million, $90.6 million and $311.7 million and $0.50 and
$1.70 for the three and twelve months ended December 31, 2008,
respectively.
References are made to results that represent certain U.S. GAAP
measures after adjustment to reflect notable items to the extent
that management believes adjusting for these items will facilitate
better comparisons across periods and more clearly indicate trends.
These non-GAAP measures are those used by management for purposes
of global business decision making, including developing budgets
and managing expenditures. Any such measures presented on a
non-GAAP basis are not prepared under a comprehensive set of
accounting rules and are not a replacement for the more
comprehensive information for investors included in IMS’s U.S. GAAP
results.
d) Reconciliation of Preliminary GAAP Cash Flows from Operating
Activities to Non-GAAP Free Cash Flow 1 Year Ended December 31
(unaudited, in millions)
2009
Note Reference
Net Cash Provided by Operating Activities (unaudited) $ 542.6
Capital Expenditures (31.6 ) 2 Proceeds from Sale of Assets,
net 5.4 2 Additions to Computer Software (85.8 ) 2 Deferred Income
Taxes 44.9 3 Net Tax Benefit on Stock-Based Compensation 4.6 4
Excess Tax Benefits from Stock-Based Compensation 0.1 4 Net
Decrease in Accrued Income Taxes 76.9 3 Net Decrease in Pension
Assets, net of Liabilities (10.0 ) 5 Net Decrease in Other
Long-Term Assets, net of Other Long-Term Liabilities (4.0 )
5 Non-GAAP Free Cash Flow (unaudited) $ 543.1 1
Notes: 1) Non-GAAP Free Cash Flow excludes certain amounts
to the extent that management believes that exclusion will
facilitate comparisons across periods and more clearly indicate
trends. Although IMS discloses adjusted Non-GAAP Free Cash Flow in
order to give a full picture to investors of the operational
performance of its business as seen by management, Non-GAAP Free
Cash Flow is not prepared under a comprehensive set of accounting
rules and is not a replacement for the more comprehensive
information for investors included in IMS's U.S. GAAP results. The
method IMS uses to prepare Non-GAAP Free Cash Flow differs in
significant respects from U.S. GAAP and is likely to differ from
the methods used by other companies. 2) Investments in
capital assets and software are integral to the ongoing business
and operations of the Company and are therefore included as part of
Non-GAAP Free Cash Flow. 3) Movements in deferred and
accrued income taxes do not necessarily relate directly to current
operations and therefore are excluded from Non-GAAP Free Cash Flow.
Accrued income taxes includes a $63.2 million net tax benefit due
to the reorganization of certain subsidiaries completed during the
three months ended March 31, 2009, which resulted in a foreign
exchange loss recognized for tax
purposes.
4) Tax benefits and expenses from stock-based compensation
are excluded from Non-GAAP Free Cash Flow as they are considered to
be financing activities. 5) Pension assets and liabilities
and other inherently long-term assets and liabilities are not
viewed as part of current operations and are therefore excluded
from Non-GAAP Free Cash Flow.
Amounts presented in the financial tables may not add due to
rounding.
These financial tables should be read in conjunction with IMS
Health’s filings previously made or to be made with the Securities
and Exchange Commission and are or will be available at
www.sec.gov.
IMS Health (NYSE:RX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
IMS Health (NYSE:RX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024